Welcome to the latest episode of Full-Court Finance, the podcast from Zacks Investment Research focused on the intersection of sports, business, and the stock market. On this week’s episode, Zacks producer and avid golfer Daniel MacPherson joins the show to discuss the current state of golf and the big business surrounding the PGA Tour as the 2018 season swings into full gear.
The golf world is abuzz with the possibility of a 2018 PGA Tour season that could see the long-awaited return to success for Tiger Woods, as his presence alone often substantially boosts television ratings and overall interest in the sport. With millions of dollars invested in television coverage, the likes of NBC (CMCSA - Free Report) , Fox (FOXA - Free Report) , CBS (CBS - Free Report) and ESPN (DIS - Free Report) are all actively rooting for Woods—who missed a majority of the last few seasons due to injuries—to remain healthy.
Still, no matter if Woods makes a real comeback or not, the PGA Tour is still a big draw for sponsors as the likes of AT&T (T - Free Report) , FedEx FDX, Microsoft (MSFT - Free Report) , Dell Technologies (DVMT - Free Report) and many other major companies are all heavily involved in golf through sponsorships and more.
On top of that, despite Nike (NKE - Free Report) exiting the golf equipment business and Adidas (ADDYY - Free Report) selling TaylorMade, the two sportswear powers are still major players in golf apparel even as struggling Under Armour (UAA - Free Report) grows its golf segment. What’s more, other golf-focused companies including Titleist and Footjoy owner Acushnet Holdings (GOLF - Free Report) and Callaway Golf (ELY - Free Report) have done well.
Lastly, despite gloomy attitudes about golf’s future, the game and business of golf are far from doomed, as amateur interest continues to be spurred by the rise of fun and recreational golf outlets such as Topgolf.
If you have any questions about this episode of Full-Court Finance please feel free to shoot us an email over at email@example.com. Please also make sure to check out all of our other podcasts at zacks.com/podcast and remember to subscribe and leave a rating in iTunes.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits. Click here to see the 5 stocks >>